Second pass at: Pharmacy supply in the UK and the questions you will be asked posts 31–54

NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

post #32 is right about the mechanism and I think understates the practical bit.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

Worth separating two things that post #30 runs together.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

Coming back to post #34, because the follow-up matters more than the original answer.

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

post #36 answers the question as asked. The question underneath it is different.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

This follows post #36 rather than contradicting it.

Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.

Coming back to post #39, because the follow-up matters more than the original answer.

Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.

Picking up post #39: that is the part I would want checked first.

Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.